Copenhagen REFORM Study Finds Blood Amylin Levels Do Not Distinguish Migraine or Predict Response to Erenumab
Researchers at the Danish Headache Center reported in Headache on October 13, 2026 that plasma amylin, a hormone closely related to the migraine signal CGRP, did not differ between 121 adults with migraine and 63 healthy controls (about 9 ng/mL in each group), across migraine subtypes, or between people who did and did not respond to 24 weeks of the CGRP-blocking antibody erenumab (Aimovig); levels also did not change during treatment. The authors concluded that blood amylin is not a useful migraine biomarker, though amylin drugs such as pramlintide can still trigger attacks.